Clinical Trial Search

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022

Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants

Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005

Primary: Progression-free Survival at 1 Year — 38 percentage of participants

Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 10 milligrams PO daily

Primary: Complete Remission — 10 participants

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants

Primary: Overall Response Rate of Pembrolizumab With Concurrent Fractionated External Beam Radiotherapy (EBRT) Among Patients With Relapsed and Refractory Non-Hodgkin Lymphoma…

Primary: Clinical Response Rate — 2; 0; 1; 1 participants

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: All Phase I-II Participants: Overall Response Rate (ORR) — 28 percentage of participants

Primary: Progression-free Survival — 56 percentage of participants

Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…

Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants

Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants

Primary: Percentage of Participants With Response — 34.7 percentage of participants

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR) — 16.7 percentage of patients

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Objective Response Rate — 3 Participants

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: Overall Response Rate — 0.0 proportion of participants

Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants